Schafer Jason J, Goff Debra A, Mangino Julie E
UPMC St. Margaret Hospital Department of Pharmacy, Pittsburgh, Pennsylvania 15215, USA.
Recent Pat Antiinfect Drug Discov. 2009 Jan;4(1):18-28. doi: 10.2174/157489109787236283.
Doripenem (DPM) is the newest antimicrobial in the carbapenem class. It is a broad spectrum agent with activity against gram-positive, gram-negative and anaerobic bacteria. in vitro Susceptibility testing has demonstrated potent activity for many drug resistant gram-negative pathogens including some that are resistant to imipenem and meropenem. It appears to be less likely to induce resistance for certain pathogens compared to the other carbapenems. The purpose of this review is to introduce DPM and describe its potential role in managing infections due to multi-drug resistant gram-negative bacteria. This article also reviews recent patents related to the carbapenem class of antimicrobials.
多立培南（DPM）是碳青霉烯类中最新的抗菌药物。它是一种广谱抗菌剂，对革兰氏阳性菌、革兰氏阴性菌和厌氧菌均有活性。体外药敏试验表明，它对许多耐药革兰氏阴性病原体具有强大的活性，包括一些对亚胺培南和美罗培南耐药的病原体。与其他碳青霉烯类药物相比，它似乎不太可能诱导某些病原体产生耐药性。本综述的目的是介绍多立培南，并描述其在治疗多重耐药革兰氏阴性菌感染中的潜在作用。本文还综述了与碳青霉烯类抗菌药物相关的近期专利。
